Biotech | May 02, 2022
NORD announces over US $ 100,000 in grant funding available for rare disease research
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Avacc 3 has significant advantages over existing whooping cough vaccines
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Subscribe To Our Newsletter & Stay Updated
